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Abstract
As a result of significant recent scientific investment, the range of vaccines available for COVID-19 prevention continues 
to expand and uptake is increasing globally. Although initial trial safety data have been generally reassuring, a number of 
adverse events, including vaccine induced thrombosis and thrombocytopenia (VITT), have come to light which have the 
potential to undermine the success of the vaccination program. However, it can be difficult to interpret available data and 
put these into context and to communicate this effectively. In this review, we discuss contemporary methodologies employed 
to investigate possible associations between vaccination and adverse neurological outcomes and why determining causality 
can be challenging. We demonstrate these issues by discussing relevant historical exemplars and explore the relevance for 
the current pandemic and vaccination program. We also discuss challenges in understanding and communicating such risks 
to clinicians and the general population within the context of the ‘infodemic’ facilitated by the Internet and other media.
Keywords Vaccination · COVID-19 · Thrombosis with thrombocytopenia syndrome · Vaccine-induced thrombocytosis 
with thrombocytopenia
Introduction
As a result of a rapid and focussed international scientific 
response to the COVID-19 pandemic, an impressive array 
of vaccines against SARS-CoV-2 is now available and the 
largest vaccination program in history is now well underway. 
However, successful global implementation will be critically 
dependent on the public health response, with uptake of at 
least 70% required to achieve “herd-immunity”. However, 
it can be difficult to interpret large-scale safety data, and 
vaccines have been historically linked to a variety of notable 
adverse neurological events. Many of these still dominate the 
popular imagination, demonstrating how difficult it can be to 
change public opinion on safety and avoid vaccine hesitancy 
after seeds of doubt have been sown.
When contemplating vaccination at such an immense 
global scale, it is particularly important to be vigilant for any 
iatrogenic harm, even when occurring at very low frequency. 
The precautionary principle warns against adopting new 
technology before sufficient evidence has accumulated about 
its effects. However, the risk of adopting a vaccine needs to 
be weighed against the population prevalence of disease, 
transmissibility, and the mortality and morbidity risk of the 
infection itself. Safety concerns should shift priority towards 
alternatives with similar efficacy and more robust safety data 
where possible but achieving an appropriate balance will 
depend on complex and dynamic contextual factors.
COVID‑19 vaccination: neurological adverse 
events
There are currently 100 vaccines in clinical development 
and more at a pre-clinical stage. Data available from phase 
III randomised clinical trials of COVID-19 vaccinations 
have been largely reassuring, although real-world experi-
ence has identified important issues for selected vaccines. 
The phase III Oxford-AstraZeneca (AZ) (Vaxzevria) vaccine 
trial reported a single case of transverse myelitis thought to 
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have been related to the vaccine [1]. Two additional cases 
were thought unrelated; one occurred in the active control 
group after 68 days and another had evidence of pre-existing 
multiple sclerosis (MS). Whether the vaccine could have 
acted as a precipitant for this presenting event is difficult to 
determine and may warrant further investigation.
Phase III trials of vaccines using mRNA technology 
from Moderna and Pfizer/BioNTech (Comirnaty) reported 
no serious adverse neurological events, apart from a slight 
excess (< 0.1%) of Bell’s palsy [2–4], a condition also noted 
in subsequent case series [5, 6]. The Janssen COVID-19 vac-
cine demonstrated a similar safety profile, with three cases 
of Bell’s palsy, 1 Guillain-Barre syndrome (GBS), and 1 
episode of brachial radiculitis occurring within 28 days of 
vaccination (versus none in placebo group). Venous throm-
boembolic events were also more common in the vaccine 
group (n = 11/21,895), one of which was a cerebral venous 
embolic event accompanied by thrombocytopenia, and four 
cases of seizures were also reported (versus 1 in the placebo 
group) [7].
However, whilst pre-licensure randomised clinical trials 
allow assessment of a vaccine’s efficacy and safety profile, 
it is important to note that the sample sizes of conventional 
vaccine trials and limited duration of follow-up are unlikely 
to reliably detect rare events. Monitoring of real-world vac-
cine experience via passive and active surveillance systems 
facilitates early detection, investigation, and analysis of 
adverse events following immunization [8] and are a key 
tool in developing an understanding of longer term and low 
frequency events as well as contextualising risks.
An example of this that could not have been detected in 
the phase 3 trials were thrombotic cases associated with 
thrombocytopenia and antibodies to PF4 reported follow-
ing the AstraZeneca (AZ) and Jannsen vaccinations [9–11]. 
As of 9th June 2021, 390 cases of vaccine induced throm-
bosis and thrombocytopenia (VITT) have occurred within 
28 days following vaccination with the COVID-19 Vaccine 
AstraZeneca in the United Kingdom where there has been a 
high early uptake. 67 were fatal after an estimated 24.6 mil-
lion first doses; (2.7 deaths/million first-dose vaccinations). 
Cerebral venous sinus thrombosis (CVST) was reported in 
140 of these cases and 250 had other major thromboembolic 
events with concurrent thrombocytopenia [12]. Current data 
seem to indicate a higher risk in younger populations; with 
possibly a higher incidence in females. In the UK, a small 
number of possible cases have also been reported to occur 
within 28 days of Pfizer vaccination (reported under peer 
review).
Determining if Vaccine Side Effects are 
Causal
Establishing a causal association between vaccination and 
an adverse outcome is no different than any other causal 
association, except that the exposure (vaccination) is well-
classified and “temporal” relationship between exposure 
and outcome well defined; hence, there is no concern about 
reverse causation. The Bradford Hill criteria are frequently 
used to guide decisions [13], but other than temporality are 
not essential, and may even be misleading if studies finding 
similar effects are “consistently” biased. Apart from chance 
associations, modern causal thinking [14] considers three 
reasons for non-causal associations that may mislead; (i) 
confounding, (ii) collider bias (including selection of indi-
viduals into the analysis1), and (iii) measurement bias. These 
problems are more pertinent for observational studies, but 




In an RCT, the randomisation of participants to either a 
treatment or control arm should avoid confounding, since 
all factors other than the exposure should be balanced across 
groups. This is true provided that the sample size is suf-
ficiently large (as in phase III RCTs) and there is adequate 
randomisation which ensures concealment of allocation. 
Adequate blinding (where neither participants, clinicians, 
or outcome assessors are aware of the treatment) also avoids 
differential measurement error such as recall or detection 
bias. However, participants or clinicians may be able to 
determine treatment despite efforts to blind (e.g., cannabi-
noids for spasticity in MS) [15]. The use of an active control 
(such as meningitis vaccine, rather than an inert placebo, as 
used with the AZ COVID vaccine) helps maintain blind-
ing more effectively. To avoid selection bias, an intention 
to treat analysis is undertaken, but excellent follow-up is 
still required; otherwise, imputation methods will need to 
be employed. In addition, whilst most RCTs are powered 
to detect common side effects such as headache, they will 
never have sufficient power to detect very rare events such 
1 Collider bias occurs if an exposure and an outcome both separately 
cause a third variable (the collider). In this situation, controlling for 
the collider (whether by study design such as preferential selection of 
participants with a certain value of the collider, or statistical analysis 
of participants not lost to follow-up) can generate a biased association 
between the exposure and outcome when none in fact exists.
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as GBS or VITT, whose detection is therefore dependent on 
alternative methodologies (see Table 1).
Observational studies
Observational studies involve no investigator-led manipula-
tion of exposure but attempt to uncover effects of an expo-
sure by comparing outcomes for people who have or who 
have not been exposed. They are more prone to bias than 
experimental studies and can lead to clinical and public con-
cern with adverse health consequences. A highly publicised 
editorial in the British Medical Journal [16] which suggested 
myopathy was common with statin treatment (seen in obser-
vational but not in the RCTs), led to patients stopping statin 
therapy, with an estimated overall increase in future cardio-
vascular events of at least 2173 over the following 10 years 
[17].
Cohort and case–control designs
Cohort studies involve a group of people unselected for 
the disorder in question, whilst case–control studies pur-
posively sample subjects with and without the disorder 
and are the most efficient design for rare outcomes (e.g., 
Creutzfeldt–Jakob disease) [18] especially if new data have 
to be collected. Recall bias is not relevant for vaccine studies 
as the exposure is usually available from medical records. 
Large cohort studies can be created using routine datasets 
with record linkage. For example, a study found no asso-
ciation between MMR vaccination and autism by linking 
vaccination status with the Psychiatric Central Register for 
all children in Denmark [19]. The usual challenge with this 
approach is to adjust for confounders that may differ between 
those getting vaccinated (or vaccinated early) and those not 
vaccinated (or vaccinated late) that themselves maybe asso-
ciated with the outcome producing a non-causal associa-
tion. There are several statistical approaches (e.g., propen-
sity matching) to help take this into account, but all rely on 
adequate measurement of potential confounders.
Alternative study designs
Case-crossover and self-controlled case series (SCCS) 
designs [20] are rarely used methods that can be particularly 
useful for short-term adverse effects, such as investigating 
Table 1  Incidence rates influence the feasibility of different study designs
CPRD Clinical Practice Research Datalink (UK)
a Sample size needed to detect a 50% increase. Assuming alpha 0.05, power 80%, follow-up for 1 year
Condition Background incidence 
per 1000 person years
Minimum sample size needed in 
each arm of a hypothetical RCT a
Appropriate study design, considering the inci-
dence
Low back pain 15–360 [93] 150 RCT 
Single unprovoked seizure 0.23–0.61 [94] 150,000 Data linkage studies, e.g., CPRD; or self-con-
trolled case series
Cerebral venous sinus thrombosis 0.01–0.02 [11] 5,000,000 National surveillance, e.g., registry of all cases in 
all of Denmark & Norway
Fig. 1  Self-controlled case 
series: example timelines of 
three participants. Averaged 
across all people in the study, 
the rate of events A occurring 
in the at-risk time period is 
compared to the rate of events 
B in the control time period. 
Many factors which in other 
designs could be confound-
ers are assumed to be constant 
within each person across their 
duration of participation. Only 
those who have experienced an 
event are included as cases
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vaccine side effects. They are equivalent to case–control 
and cohort studies, but subjects who are cases or who are 
exposed, also act as their own controls or unexposed indi-
viduals (see Fig. 1). This is especially helpful where data on 
confounders are absent or poorly measured, but it assumes 
that confounders are fixed over a short time. An SCCS 
study of myocardial infarction observed a three-to-fourfold 
increased risk ratio in the first week post-acute infection 
(but not post-vaccination), an effect which disappeared with 
longer risk periods [21].
Ecological studies, natural experiments, and time series 
analyses
Ecological studies (which compare data at the group not the 
individual level) are usually regarded as low on the hier-
archy of evidence as they are prone to the ecological fal-
lacy (confounding at a group level). However, in relation to 
vaccine exposure, they may be conceptualised as a natural 
experiment. If the choice of vaccine or speed of delivery is 
related to political factors and not the risk of the outcome 
in the population, then individual confounding should not 
be present, similar to an RCT. For example, rare cases of 
VITT may have become evident in some countries before 
others, due to the earlier use of the AZ vaccine in younger 
age groups in certain countries. Countries like Israel which 
have only used the Pfizer vaccine can act as a control popu-
lation for other countries that have also used AZ such as 
the UK, although there may be racial/ethnic differences in 
risk of outcomes across countries. Within-country analyses 
can also be performed using interrupted time series analyses 
(i.e., examining rates of a disorder, at the population level, 
before and after an index date) with vaccine licensing as the 
index date. This is more problematic when several vaccines 
are used concurrently.
Case series and surveillance systems (EudraVigilance; 
Yellow Card)
Individual case reports have no capacity to assess whether a 
vaccination and adverse event are causally linked, except by 
appealing to the temporal interval and biological plausibility 
(e.g., an episode of anaphylaxis within 15 min of vaccina-
tion). Case series ideally describe all consecutive cases of 
a disorder presenting to a clinical service, with the aim of 
discovering shared predictors that could be causes. Near-
real-time pharmacovigilance databases (such as Yellow Card 
in the UK, and EudraVigilance) are set up with the aim of 
rapidly identifying any possible safety concerns. These are 
essentially very large-scale case series, which enable post-
marketing surveillance, and are especially useful for rare 
events. Following the identification of a possible signal, epi-
demiological studies should then be performed to test and 
quantify any potential cause–effect relationships in a more 
rigorous fashion (see Fig. 2 below).
Accounting for functional neurological disorder 
(FND) reactions following vaccination
Non-placebo-controlled studies need to consider the pos-
sibility of “nocebo” events (adverse effects experienced 
and reported in the context of negative expectations around 
an intervention). Functional Neurological Disorder (FND) 
reactions to vaccination can be conceptualised as a complex 
reaction to a nocebo effect. Heightened stress levels dur-
ing pandemics, feelings of uncertainty around the vaccine, 
and transient physical discomfort likely combine to make 
such reactions more common. These may be amplified by 
intense media interest focussed on neurological symptoms 
(initially reported as unexplained) [22, 23]. This means 
that such cases are considerably more likely to show up in 
post-marketing surveillance than in the initial trials [23, 
24]. Unfortunately, systematic incidence data are lacking; 
at best a case (listed as FND or conversion disorder) will 
be mentioned in passing in studies set up to look for other 
conditions [25–27]. Such events are more likely to occur in 
settings where many (especially young) patients are vac-
cinated at once [28]. Clusters of cases have led to delayed 
rollout of vaccination programs [29]. One study from Roch-
ester, New York (1978) collated systematic reporting of 
post-vaccination concerns reported to a local health clinic. 
This study began the morning after the swine flu vaccination 
was cancelled due to GBS fears, at which time there was 
much media speculation detailing neurological symptoms 
and their potential connection to the vaccine [30]. The rate 
of reactions found was far higher than the number of GBS 
cases separately documented in the wider area, though none 
of the conversion reactions had come to the attention of the 
local neurologist.
FND symptoms appear to be common post-vaccination 
and may have a high healthcare burden. They can be chal-
lenging to diagnose because of the wide variety of poten-
tial symptoms, often presenting to non-specialists and are 
often under-reported. Greater clarity on diagnosis and sys-
tematic reporting should allow quantification, with benefits 
for patient education as well as wider scientific and social 
understanding of functional disorders.
Lessons learnt from history
The long history of vaccination provides some important 
lessons in determining (non) causal links between vaccina-
tion and illnesses. This section provides selected historical 
exemplars, which remain of value when considering emerg-
ing data from contemporary vaccination programs.
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Contextualising risk: influenza vaccination 
and Guillain‑Barre syndrome
In 1976, an unexpected increase in GBS cases was linked 
to a mass vaccination program against swine flu, resulting 
in its suspension in the United States [31]. Later, during the 
2009 H1N1 influenza pandemic, a high degree of public 
interest in the safety of the vaccine (also of swine origin) 
saw the adoption of safety surveillance systems [32]. Sev-
eral studies have since addressed the possible association 
between seasonal or pandemic influenza vaccinations and 
GBS resulting in varying risk estimates; most of which 
are consistent with chance variation. Contemporary meta-
analyses have reported pooled risk estimates of 1.15–1.22 
(95% CI 0.97–1.35; 1.01–1.48) [33, 34]. More recently, an 
SCCS analysed all GBS cases occurring in influenza seasons 
2010–2014 [35]. Incidence of GBS in the exposure period 
(day 1–42 following vaccination) was compared to that in 
the control period and no increased risk of GBS was identi-
fied (Risk  Ratiocrude 1.02; 95% CI 0.83–1.25; p = 0.85). Con-
versely a large systematic review and meta-analysis in 2020 
found that previous influenza-like illness was significantly 
associated with GBS, with an effect size of 9.6 (95% CI 
4.0–23.0) [33], highlighting the much larger risk in unvac-
cinated populations.
It is thought that there may be an increased risk for devel-
oping GBS from pandemic influenza vaccinations such as 
H1N1 (RR = 1.84; 95% CI 1.36–2.50) compared to sea-
sonal vaccination (RR = 1.22; 95% CI 1.01–1.48) [34]. This 
finding is in line with the other studies showing a slight 
increased risk of GBS [36–42]. However, other studies have 
failed to confirm this association [43–45].
Overall, there appears to be a consensus for a small asso-
ciation between influenza vaccines and GBS, but the risk is 
consistently very low (~ 1–3 additional GBS cases per mil-
lion vaccinations) [46] and needs to be carefully weighed 
against evidence supporting benefits of vaccination in 
preventing influenza-related complications, including an 
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Fig. 2  Hypothetical illustration of how potential vaccine-related complications could be investigated. NNTH = number needed to treat for harm
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• Large-scale prospective surveillance registers can offer 
key data in comparative estimations of risk.
• There is rarely a zero-risk option; the risk of complica-
tions from preventable disease may be higher than risk 
of complications from vaccination itself, particularly in 
periods of high disease transmission.
Consequences of a false‑positive signal: hepatitis B 
vaccination and multiple sclerosis
In the early 1990s, French authorities undertook an immu-
nization programme against hepatitis B (HB) targeting at-
risk adults, infants, and pre-adolescents. Case reports then 
began to emerge raising concerns that HB vaccination was 
linked to autoimmune diseases, including Multiple Sclerosis 
(MS). Subsequently, case–control studies [48, 49] identi-
fied a slight increase in the risk of MS/demyelination in the 
months following HB vaccination, leading to suspension 
of the school-based adolescent vaccination programme in 
1998. 624 demyelination cases were reported to the French 
Medicines Agency (FMA) between 1981 and 2000 possibly 
linked to HB vaccination of which 422 were a first episode 
of MS [50]. However, it is important to note that although 
the vaccination program was targeted at new-borns, children, 
and at-risk adults, a disproportionately higher number of 
adolescents and young adults were vaccinated—at an age 
where demyelination risk is highest [50]. Expert consensus 
panels organised by the French authorities failed to confirm 
an increased risk [51–54], but the damage in public confi-
dence resulted in a legacy of distrust and low vaccination 
rates [55, 56], which even now may be reflected in the cur-
rent national COVID-19 vaccination program [57].
Although a small number of case–control studies have 
since reported an increase in risk of a first demyelinating 
event in the first few months following vaccination [58–60], 
the majority of case–control and observational studies have 
failed to demonstrate a significantly increased risk [60–69]. 
A French MS Society task force set up in 2017 eventually 
concluded that there was no evidence for an association [70] 
and recent meta-analyses have supported this position [71]. 
Only one study has addressed the risk of MS relapse with 
HBV, and also failed to identify an association [66].
Key points
• Vaccination programs often target at-risk groups which 
may have a higher background incidence rate of an event 
than the rest of the population.
• Initial unresolved reports can have profound and last-
ing consequences for public confidence. Data analysis 
should focus on the highest-quality studies and the best 
amalgamation of evidence.
Expect the unexpected: Pandremix© vaccination 
and narcolepsy
In April 2009, the H1N1 A/California pandemic influenza 
strain spread globally. Rapid development of influenza vac-
cines followed. Pandremix, an adjuvanted vaccine produced 
by GlaxoSmithKline (GSK), was administered with over 
31 million doses primarily in Europe [72]. By August 2010, 
a possible association between narcolepsy and Pandremix 
had been reported in Sweden and Finland [73, 74], resulting 
in epidemiological studies being set up across Europe.
Following analysis of data from a retrospective cohort 
study in 2012 [75], the Finnish National Institute for Health 
and Welfare estimated the relative risk for narcolepsy after 
Pandremix in children aged 4–19 was large at 12.7 (95% 
CI 6.1–30.8). International retrospective cohort studies per-
formed on newly diagnosed narcolepsy patients [75–81] and 
a recent meta-analysis have estimated an increase in relative 
risk of 5–14-fold in vaccinated children and adolescents, and 
3–8-fold in adults within the first year of vaccination with 
Pandremix [82]. Studies conducted in South Korea and the 
United States using alternative H1N1 vaccines did not report 
an increased risk [83, 84]. Retrospective cohort and case-
control studies have also identified an increased incidence 
of narcolepsy following influenza [85, 86], although others 
have shown that this was not the main factor contributing to 
narcolepsy [87].
The Pandremix and narcolepsy association illustrates an 
appropriately investigated observed signal with confirmation 
across multiple studies, despite a potential for ascertainment 
bias [88], and several countries now offer compensation for 
Pandremix-associated narcolepsy.[89].
Key points
• International systems should be in place to rapidly inves-
tigate possible rare adverse events.
• It may be problematic to distinguish adverse events 
occurring during periods of high background infection 
rates from those secondary to vaccination.
How to make sense of emerging data
Many contextual factors need to be considered when evalu-
ating concerns around possible vaccine side effects. The 
background rate of a particular outcome will affect the 
power to detect an observed increase from the background 
rate (Table 1). This is problematic for rare events, even in a 
generously sized RCT, necessitating different approaches.
Following licensing, post-marketing surveillance is cru-
cial to detect signals of potential concern. One drawback 
of these surveillance systems is the need for an appropri-
ate comparator group. Considerable difficulties arose when 
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evaluating early signals of VITT, since prevalence estimates 
of CVST are scarce, let alone the highly unusual combina-
tion of abnormalities in VITT. Finding a rate higher than the 
background can be misleading, for example through ascer-
tainment or reporting bias (e.g., a patient or clinician being 
more mindful of the potential for novel side effects in the 
context of scientific and media interest in the new vaccine). 
Therefore, where concern remains, this needs investigation 
via a study design that has a larger sample size than would 
be possible in an RCT, an adequate comparator population 
or using a self-controlled design (see Fig. 2).
In a pandemic situation, it is also necessary to consider 
whether a newly prevalent symptom could be the outcome 
of the infection rather than vaccination [90]. This might alter 
the expected baseline incidence compared to studies con-
ducted in pre-pandemic times.
Fighting misinformation in the age of social 
media
Vaccination policy needs to balance the risks of using versus 
not using a vaccine, which includes: (i) the risk of otherwise 
contracting the infection, (ii) the risk of serious complica-
tions post-infection, and (iii) whether there is an alterna-
tive vaccine with a more favourable side effect profile. This 
decision must incorporate the prevailing rate of infections, 
personal comorbidities, and whether any potential vaccine 
side effects differentially affect certain high-risk groups. 
This complicates any simple public health decision or mes-
sage. Communicating this complexity can be aided by visual 
representations of key factors [such as that used by the UK 
government communications in Spring 2021 to explain the 
benefits and harms of the AZ vaccine by age group (see 
Fig. 3)].
Those who are critical or anti-vaccination will inevitably 
highlight the potential harms and down-play the benefits. 
This is a particular issue in the age of enhanced technologi-
cal and social media accessibility. The general population is 
faced with a deluge of information rapidly disseminated over 
the Internet and media. Whilst this ‘infodemic’ may have 
distinct advantages in logistical organisation and effective 
public communication, it may also be countered by disin-
formation spreading “vaccine hesitancy” and threatening 
uptake [91, 92]. Public education and actively countering 
misinformation will be essential in increasing worldwide 
acceptance and vaccine uptake if we are to achieve “herd 
immunity”.
Conclusion
Any new vaccine will have been carefully studied in large 
randomised trials before licencing. These can never be big 
enough to detect all possible adverse events and national 
surveillance systems are required to obtain post-marketing 
Fig. 3  A visual depiction of balancing the benefits and harms when 
making population vaccination decisions. This shows how recom-
mendations vary by age and prevailing infection rates. Reproduced 
with permission from A. Freeman and D. Spiegelhalter; for more 
information, see https:// winto ncent re. maths. cam. ac. uk/ accessed 
17/06/21
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data and need to be combined using harmonised datasets 
that span international boundaries. Such analyses require 
appropriate governance data sharing and the necessary infra-
structure to undertake anonymised individual patient data 
analyses. However, all post-marketing reports tend to be 
affected by bias and should be treated with caution with fur-
ther well-designed and robust studies required to confirm or 
refute associations between vaccination and adverse events. 
Importantly, increased rates of adverse events may be due to 
the disease itself or a higher risk in the population targeted 
for initial vaccination, even without vaccination. Public mes-
saging must be carefully measured, since the consequences 
of misreporting may be profound. Even where association is 
confirmed, contextualisation of risk is important, as risks of 
infection may far exceed those of adverse events, particularly 
in periods of high disease transmission. In addition, risks 
can be effectively mitigated by targeting strategies, timely 
dissemination of appropriate information, and effective pub-
lic engagement.
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